El.En. SpAMIL:ELN +0.42%76 EBITDA Margin % is 16.26% as of Mar. 2026, which is 23% above its 10-year median of 13.24. GuruFocus rates MIL:ELN with a GF Score™ of 76/100 and a GF Value™ of €11.57 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, El.En. SpA ranks better than 62.99% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. El.En. SpA's EBITDA for the
three
months ended in Mar. 2026 was €23.7 Mil. El.En. SpA's Revenue for the
three
months ended in Mar. 2026 was €145.6 Mil. Therefore, El.En. SpA's EBITDA margin for the quarter that ended in Mar. 2026 was 16.26%.
El.En. SpA (MIL:ELN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
El.En. SpA EBITDA Margin % Related Terms
El.En. SpA EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for El.En. SpA's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:ELN vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, El.En. SpA's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
El.En. SpA EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, El.En. SpA's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where El.En. SpA's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El.En. SpA (MIL:ELN) has a EBITDA Margin % of 16.26% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on El.En. SpA and its competitors. This is 23% above median its historical median of 13.24. Over the past decade, El.En. SpA's EBITDA Margin % has ranged from 8.83 to 22.45. According to the industry distribution chart, El.En. SpA ranks #302 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 37%.
Is El.En. SpA's EBITDA Margin % too high?
El.En. SpA's current EBITDA Margin % of 16.26% is 23% above median its 10-year median of 13.24. Over the past 10 years, this metric has ranged from a low of 8.83 to a high of 22.45. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. El.En. SpA's value of 16.26% is 117.5% above this industry median. Based on the distribution chart, El.En. SpA ranks #302 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, El.En. SpA has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does El.En. SpA's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, El.En. SpA ranks #302 out of 816 companies for EBITDA Margin %. This puts El.En. SpA in the upper half of its industry. The industry median EBITDA Margin % is 7.48. El.En. SpA's value of 16.26% is 117.5% above this benchmark. Historically, El.En. SpA's own EBITDA Margin % has ranged from 8.83 to 22.45 over the past decade. While the company's 10-year median is 13.24 vs. the industry median of 7.48, El.En. SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. El.En. SpA's current EBITDA Margin % of 16.26% is 117.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on El.En. SpA and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. El.En. SpA's current EBITDA Margin % is 16.26%, which is 23% above median its own 10-year median of 13.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is El.En. SpA stock overvalued right now?
Based on GuruFocus' analysis, El.En. SpA (MIL:ELN) is currently considered Significantly Overvalued. The stock's GF Value™ is €11.57, compared to a current price of €16.77 — trading 44.9% above its estimated fair value. The current EBITDA Margin % is 16.26%, which is 23% above median its 10-year median of 13.24 and 117.5% above the Medical Devices & Instruments industry median of 7.48. El.En. SpA's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For El.En. SpA (MIL:ELN), the current EBITDA Margin % is 16.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is El.En. SpA (MIL:ELN) Overvalued in 2026?
Based on GuruFocus' analysis, El.En. SpA stock appears to be overvalued.
The current stock price of €16.77 is trading 44.9% above its estimated GF Value™ of €11.57.
GuruFocus considers El.En. SpA to be Significantly Overvalued.
Key valuation signals for MIL:ELN:
EBITDA Margin %: 16.26% (23% above median its 10-year median of 13.24)
GF Value™: €11.57 vs. price of €16.77 (44.9% above fair value)
Industry Position: 117.5% above the Medical Devices & Instruments median (#302 of 816)
No single metric tells the full story. See the MIL:ELN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
El.En. SpA is engaged in the research and development, manufacturing, distribution, and sales of laser systems. The company operates in two divisions: medical and industrial. In the medical division, the application of laser is used as a healing treatment for aesthetic, surgical, physiotherapy and dental. Industrial division develops solutions for laser material processing applications through cutting, marking, laser sources and restoration. The company generates the majority of its revenue from the medical division. Geographically, it derives maximum revenue from the Rest of the World.
76GF Score
Get the complete analysis for MIL:ELN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ELN has been successfully added to your 
